CoChat
Sign Up
Cited by 65Nicotinic Acetylcholine Receptors StudySmoking Behavior and CessationNeuroscience and Neuropharmacology Research

Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT

Open access
Mitsis, Effie M., Cosgrove, Kelly P., Staley, Julie K., Bois, Frederic, Frohlich, Erin B., Tamagnan, Gilles D., Estok, Kristina M., Seibyl, John P. +1 more·2009·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2007.12.008PMC PMC3523217
Open this paper in CoChat — free account

Abstract

Human postmortem studies have reported decreases with age in high affinity nicotine binding in brain. We investigated the effect of age on beta(2)-containing nicotinic acetylcholine receptor (beta(2)-nAChR) availability in eight brain regions of living human subjects using the ligand [(123)I]5-IA-85380 ([(123)I]5-IA) and single photon emission computed tomography (SPECT). Healthy, nonsmokers (N=47) ranging in age from 18 to 85 were administered [(123)I]5-IA using a bolus plus constant infusion paradigm and imaged 6-8h later under equilibrium conditions. The effect of age on regional beta(2)-nAChR availability (V(T), regional brain activity/free plasma parent, a measure proportional to the binding potential) was analyzed using linear regression and Pearson's correlation (r). Age and regional beta(2)-nAChR availability were inversely correlated in seven of the eight brain regions analyzed, with decline ranging from 32% (thalamus) to 18% (occipital cortex) over the adult lifespan, or up to 5% per decade. These results in living human subjects corroborate postmortem reports of decline in high affinity nicotine binding with age and may aid in elucidating the role of beta(2)-nAChRs in cognitive aging.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2007.12.008

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 39

  1. [1]Benwell MEM, Balfour DJK, Anderson JM. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding site in human brain. J Neurochem. 1988;50(4):1243–1247. doi: 10.1111/j.1471-4159.1988.tb10600.x. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  2. [2]Chang L. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;NS-25:638–543. [Google Scholar]
  3. [4]Court J, Piggott M, Perry E, Barlow R, Perry R. Age-associated decline in high affinity nicotine binding in human brain frontal cortex does not correlate with the changes in choline acetyltransferase activity. Neurosci Res Comm. 1992;10:125–133. [Google Scholar]
  4. [5]Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer’s disease. Biol Psychiatry. 2001;49(3):175–184. doi: 10.1016/s0006-3223(00)01116-1. [DOI] [PubMed] [Google Scholar] · DOI
  5. [6]Court JA, Lloyd S, Johnson M, Griffiths M, Birdsall NJ, Piggott MA, Oakley AE, Ince PG, Perry EK, Perry RH. Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Develop Brain Res. 1997;101(1-2):93–105. doi: 10.1016/s0165-3806(97)00052-7. [DOI] [PubMed] [Google Scholar] · DOI
  6. [7]Flynn DD, Mash DC. Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer’s disease and the normal. J Neurochem. 1986;47(6):1948–1954. doi: 10.1111/j.1471-4159.1986.tb13113.x. [DOI] [PubMed] [Google Scholar] · DOI
  7. [8]Folstein MF, Fostein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  8. [9]Fujita M, Tamagnan G, Zoghbi SS, Al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB. Measurement of a4b2 nicotinic acetylcholine receptors with [123I]5-I-A-85830 SPECT. J Nucl Med. 2000;41(9):1552–1560. [PubMed] [Google Scholar]
  9. [10]Fujita M, Seibyl JP, Vaupel DB, Tamagnan G, Early M, Zoghbi SS, Baldwin RM, Horti AG, Koren AO, Mukhin AG, Khan S, Bozkurt A, Kimes AS, London ED, Innis RB. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123I]5-I-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging. 2002;29(2):183–190. doi: 10.1007/s00259-001-0695-z. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  10. [11]Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, Bozkurt A, Seneca N, Tipre D, DeNucci C, Iida H, Vaupel DB, Horti AG, Koren AO, Kimes AS, London ED, Seibyl JP, Baldwin RM, Innis RB. Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging. 2003;30(12):1620–1629. doi: 10.1007/s00259-003-1320-0. [DOI] [PubMed] [Google Scholar] · DOI
  11. [12]Hellström-Lindahl E, Winblad B, Nordberg A. Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics. Brain Res. 1993;620(1):42–48. doi: 10.1016/0006-8993(93)90268-r. [DOI] [PubMed] [Google Scholar] · DOI
  12. [13]Hellström-Lindahl E, Court JA. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behav Brain Res. 2000;113(1-2):159–168. doi: 10.1016/s0166-4328(00)00210-2. [DOI] [PubMed] [Google Scholar] · DOI
  13. [14]Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572. doi: 10.1192/bjp.140.6.566. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  14. [15]Jernigan TL, Archibald SL, Berhow MT, Sowell ER, Foster DS, Hesselink JR. Cerebral structure on MRI, Part I: Localization of age-related changes. Biol Psychiatry. 1991;29(1):55–67. doi: 10.1016/0006-3223(91)90210-d. [DOI] [PubMed] [Google Scholar] · DOI
  15. [16]Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology (Berl) 2006;188(4):509–520. doi: 10.1007/s00213-006-0447-7. [DOI] [PubMed] [Google Scholar] · DOI
  16. [18]Levin E. Nicotinic systems and cognitive function. Psychopharmacology. 1992;108(4):417–431. doi: 10.1007/BF02247415. [DOI] [PubMed] [Google Scholar] · DOI
  17. [19]Levin E. Nicotinic receptor subtypes and cognitive function. J Neurobiol. 2002;53(4):633–640. doi: 10.1002/neu.10151. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  18. [20]Mamede M, Ishizu K, Ueda M, Mukai T, Iida Y, Fukuyama H, Saga T, Saji H. Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J Nucl Med. 2004;45(9):1458–1470. [PubMed] [Google Scholar]
  19. [21]Marutle A, Warpman U, Bogdanovic N, Nordberg A. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+/-)-[3H]epibatidine. Brain Res. 1998;801(1-2):143–149. doi: 10.1016/s0006-8993(98)00558-7. [DOI] [PubMed] [Google Scholar] · DOI
  20. [22]Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, Lin MP, Price JC. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med. 1999;40(12):2053–2065. [PubMed] [Google Scholar]
  21. [23]Mitsis EM, Cosgrove KP, Staley JK, Frohlich E, Bois F, Tamagnan GD, Estok K, Seibyl JP, van Dyck CH. [123I]5-IA-85380 SPECT imaging of β2-nicotinic acetylcholine receptor availability in the aging human brain. Ann NY Acad Sci. 2007;1097:168–170. doi: 10.1196/annals.1379.015. [DOI] [PubMed] [Google Scholar] · DOI
  22. [25]Nordberg A, Adolfsson R, Marcusson K, Winblad B. Cholinergic receptors in the hippocampus in normal aging and dementia of Alzheimer type. In: Giacobini E, Filogam G, Giacobini F, Vernadahis A, editors. The Aging Brain: Cellular and Molecular Mechanisms of Aging in the Nervous System Aging. Vol. 20. New York: Raven Press; 1982. pp. 231–245. [Google Scholar]
  23. [26]Nordberg A, Winblad B. Brain nicotinic and muscarinic receptors in normal aging and dementia. In: Fisher A, Hanin I, Lachman C, editors. Alzheimer’s and Parkinson’s Disease: Strategies for Research and Development. New York: Plenum; 1986. pp. 95–108. [Google Scholar]
  24. [27]Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res. 1992;31(1):103–111. doi: 10.1002/jnr.490310115. [DOI] [PubMed] [Google Scholar] · DOI
  25. [28]Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord. 1995;9(1):21–27. doi: 10.1097/00002093-199505000-00006. [DOI] [PubMed] [Google Scholar] · DOI
  26. [29]Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Hellstrom-Lindahl E, Langstrom B. Imaging of nicotinic and muscarinic receptors in Alzheimer’s disease: Effect of tacrine treatment. Dement Geriatr Cogn Disord. 1997;8(2):78–84. doi: 10.1159/000106611. [DOI] [PubMed] [Google Scholar] · DOI
  27. [30]O’Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED. Alpha4 beta2 nicotinic receptor status in Alzheimer’s disease using 123I-5IA-85380 SPECT. J Neurol Neurosurg Psychiatry. 2007;78(4):356–362. doi: 10.1136/jnnp.2006.108209. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  28. [31]Perry DC, Dávila-García MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: Membrane binding and autoradiography studies. J Pharmacol Exp Therap. 1999;289(3):1545–1552. [PubMed] [Google Scholar]
  29. [32]Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ, Candy JM, Edwardson JA, Fairbairn A. Cholinergic receptors in cognitive disorders. Can J Neurol Sci. 1986;13(4 Suppl):521–527. doi: 10.1017/s0317167100037240. [DOI] [PubMed] [Google Scholar] · DOI
  30. [33]Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH. Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience. 1995;64(2):385–395. doi: 10.1016/0306-4522(94)00410-7. [DOI] [PubMed] [Google Scholar] · DOI
  31. [34]Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry. 2001;49(3):258–267. doi: 10.1016/s0006-3223(00)01094-5. [DOI] [PubMed] [Google Scholar] · DOI
  32. [35]Staley JK, van Dyck CH, Weinzimmer D, Brenner E, Baldwin RM, Tamagnan GD, Riccardi P, Mitsis EM, Seibyl JP. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med. 2005;46(9):1466–1472. [PubMed] [Google Scholar]
  33. [37]Sullivan EV, Rosenbloom M, Serventi K, Pfefferbaum A. Effects of age and sex on volumes of the thalamus, pons, and cortex. Neurobiol Aging. 2004;25(2):185–192. doi: 10.1016/s0197-4580(03)00044-7. [DOI] [PubMed] [Google Scholar] · DOI
  34. [38]Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Mihara M. Age-related changes in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human frontal cortex and hippocampus. Neuroscience Lett. 1998;245(3):139–142. doi: 10.1016/s0304-3940(98)00205-5. [DOI] [PubMed] [Google Scholar] · DOI
  35. [39]Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Mihara M. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human putamen. Implications for susceptibility to parkinsonism. Brain Res. 1998;791(1-2):186–190. doi: 10.1016/s0006-8993(98)00093-6. [DOI] [PubMed] [Google Scholar] · DOI
  36. [40]van Dyck CH, Soares JC, Tan PZ, Staley JK, Baldwin RM, Amici LA, Fu X, Garg PK, Seibyl JP, Charney DS, Innis RB. Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med Biol. 2000;27(8):715–722. doi: 10.1016/s0969-8051(00)00160-8. [DOI] [PubMed] [Google Scholar] · DOI
  37. [41]van Dyck CH, Tan PZ, Baldwin RM, A LA, Garg PK, Ng CK, Soufer R, Charney DS, Innis RB. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. J Nucl Med. 2000;41(2):234–241. [PubMed] [Google Scholar]
  38. [42]Walhovd KB, Fjell AM, Reinvang I, Lundervold A, Dale AM, Eilertsen DE, Quinn BT, Salat D, Makris N, Fischl B. Effects of age on volumes of cortex, white matter and subcortical structures. Neurobiol Aging. 2005;26(9):1261–1270. doi: 10.1016/j.neurobiolaging.2005.05.020. [DOI] [PubMed] [Google Scholar] · DOI
  39. [43]Zoghbi S, Tamagnan G, Baldwin RM, Tikriti MA, Amici L, Seibyl J, Innis R. Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol. 2001;28(1):91–96. doi: 10.1016/S0969-8051(00)00188-8. [DOI] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Mitsis, E. M., Cosgrove, K. P., Staley, J. K., Bois, F., Frohlich, E. B., Tamagnan, G. D., Estok, K. M., Seibyl, J. P., & van Dyck, C. H.
Affiliations
Yale University (US)
ORCID
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2009-09
Volume
30
Issue
9
Pages
1490-1497
ISSN
0197-4580 (ISSN-L)
DOI
10.1016/j.neurobiolaging.2007.12.008
PMC
PMC3523217
OpenAlex
W2034839825
Cited by
65
References
4
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 5 · 2015: 4 · 2014: 5 · 2013: 6 · 2012: 4
FWCI
1.90
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Alcohol Abuse and Alcoholism (P50AA015632)
  • National Institute on Drug Abuse (R01DA015577)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
nicotinic acetylcholine receptors, beta2 nAChR, age-related decline, receptor availability, SPECT imaging, nicotine binding, cognitive aging, brain regions, thalamus, occipital cortex
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Aging, Azetidines, Brain, Brain Chemistry, Cognition Disorders, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Pyridines, Receptors, Nicotinic, Down-Regulation, Tomography, Emission-Computed, Single-Photon, Linear Models, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review